Moreover, the high expression of DLL3 in the SCLC-A subtype [22] might eventually make it a promising target for agents such as tarlatamab, a bi-specific T cell engager, which acts by binding both DLL3 and CD3 [21]. Here, DLL3 is linked to small cell lung carcinoma.